TriNetX, a US-based provider of real-world data and real-world evidence solutions, and Japanese ICT company Fujitsu (TYO:6702) announced on Wednesday the launch of a joint venture, TriNetX Japan K.K., to expand access to real-world data for clinical trials and drug development.

The partnership integrates TriNetX's global patient data network with Fujitsu's cloud-based healthcare platform to facilitate research across Japan.

As the world's third-largest pharmaceutical market, Japan presents significant opportunities for drug discovery, particularly in age-related diseases such as cancer and cardiovascular disorders. The initiative aims to accelerate clinical research by enabling secure access to anonymised electronic health records (EHR).

The TriNetX LIVE Platform will connect Japanese medical institutions with life sciences companies, enhancing data-driven healthcare innovation.

The joint venture also aligns with the growing participation of Japanese institutions in the TriNetX network. Researchers are leveraging TriNetX's technology to conduct new studies, while pharmaceutical firms are expanding clinical trial opportunities in Japan.